YAP1 Is a Prognostic Marker and Its Inhibition Reduces Tumor Progression in Adrenocortical Tumors
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgaf013 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Candy C B More und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, SP 14049-900, Brazil. Hauptthemen laut MEDLINE: Adrenal Cortex Neoplasms, Adaptor Proteins, Signal Transducing, Transcription Factors, Biomarkers, Tumor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Sao Paulo Research Foundation.
Abstract (Originalsprache)
Context
Adrenocortical cancer (ACC) is rare and aggressive, with YAP1 overexpression associated with poor outcomes in pediatric patients.
Objective
In this study, we investigated the mechanisms by which YAP1 drives ACC progression and explored it as a potential target therapy.
Methods
YAP1 expression and methylation in ACC were analyzed from pediatric and adult cohorts. The role of YAP1 on ACC progression was examined in vitro using an adrenocortical cell line. Also, was evaluated the YAP1's influence on β-catenin. The effect of YAP1 pharmacological inhibition was assessed on tumor growth in a murine xenograft model of ACC.
Results
High YAP1 expression was associated with lower survival in all cohorts. The YAP1 methylation signature was associated with patients’ prognosis. Inhibition of YAP1 reduced ACC cell viability through cell cycle arrest in the G0/G1 phase, and inhibited the epithelial–mesenchymal transition and cell invasion. YAP1 modulated β-catenin protein levels and transcription activity, whereas β-catenin partially mediated the effect of YAP1 on adrenocortical tumorigenesis. In vivo, verteporfin impaired tumor growth and Ki67 immunoreactivity in xenografts.
Conclusion
YAP1 is a potential novel prognostic marker in patients with ACC. Its deregulation contributes to adrenocortical tumorigenesis partially through crosstalk between Hippo/YAP1 and Wnt/β-catenin pathways. YAP1 inhibition is a new antitumor target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, SP 14049-900, Brazil.
- Hematology Division, LIM31, Medical School, University of Sao Paulo, Ribeirao Preto, SP 01246-903, Brazil.
- Department of Pathology, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, SP 14049-900, Brazil.
- Boldrini Children's Center, State University of Campinas, Campinas, SP 13083-210, Brazil.
- Department of Pediatrics - Pediatric Oncology Division, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, SP 14049-900, Brazil.
- Department of Internal Medicine, Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, SP 14049-900, Brazil.
ORCID-Profile: Sonir R R Antonini
Förderung
- Sao Paulo Research Foundation
Zitieren
APA
More, C. C. B., Bueno, A. C., Rojas, C. A. O., Stecchini, M. F., Ramalho, F. S., Brandalise, S. R., Cardinalli, I. A., Yunes, J. A., Junqueira, T., Scrideli, C. A., Castro, M., & Antonini, S. R. R. (2025). YAP1 Is a Prognostic Marker and Its Inhibition Reduces Tumor Progression in Adrenocortical Tumors. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf013
Vancouver
More CCB, Bueno AC, Rojas CAO, Stecchini MF, Ramalho FS, Brandalise SR, et al. YAP1 Is a Prognostic Marker and Its Inhibition Reduces Tumor Progression in Adrenocortical Tumors. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf013
BibTeX
@article{More2025,
author = {More, Candy C B and Bueno, Ana Carolina and Rojas, César A O and Stecchini, Mônica F and Ramalho, Fernando S and Brandalise, Silvia R and Cardinalli, Izilda A and Yunes, José Andres and Junqueira, Thais and Scrideli, Carlos A and Castro, Margaret and Antonini, Sonir R R},
title = {YAP1 Is a Prognostic Marker and Its Inhibition Reduces Tumor Progression in Adrenocortical Tumors},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgaf013}
}
EUVIMED